ARTICLE | Company News
Rexahn deal
July 6, 2009 7:00 AM UTC
Rexahn granted an undisclosed "top 20 global pharmaceutical company" an option for an exclusive, worldwide license to develop and commercialize RX-3117. The small molecule nucleoside inhibitor of DN...